Resistance to HER2-targeted therapy: Mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment

Wiener Medizinische Wochenschrift

Volumn 160, Issue 19-20, 2010, Pages 506-512

  Hubalek, Michael ^a   Brunner, Christine ^a   Matthä, Karin ^a   Marth, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Gefitinib; HER2 positive breast cancer; IGFR; Lapatinib; P13k; Pertuzumab; PTEN; Strategies to overcome resistance; Trastuzumab resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; NERATINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TARGETING; HUMAN; METASTASIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASE; PROGNOSIS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 78651387936     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0838-6     Document Type: Article

References (24)

1. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 61:4744-4749, 2001.
2. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology, 61 (Suppl. 2):1-13, 2001.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2:127-137, 2001.
4. Barok M, Isola J, Pályi-Krekk Z, et al. Trastuzumab causes antibodydependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther, 6:2065-2072, 2007.
5. Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer, 113:1294-1301, 2008.
6. Zabrecky JR, Lam T, McKenzie SJ, et al. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem, 266:1716-1720, 1991.
7. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol, 26:1789-1796, 2008.
8. Valabrega G, Montemurro F, Sarotto I, et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene, 24:3002-3010, 2005.
9. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6:117-127, 2004.
10. Fujita T, Doihara H, Kawasaki K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer, 94:247-252, 2006.
11. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst, 93:1852-1857, 2001.
12. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res, 65:11118-11128, 2005.
13. Nagy P, Friedländer E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res, 65:473-482, 2005.
14. Nanda, R. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials, 2:111-116, 2007.
15. Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, atruncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst, 99:628-638, 2007.
16. D'Alessio A, De Luca A, Maiello MR, et al. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat, 123:387-396, 2010.
17. Normanno N, Morabito A, De Luca A, et al. Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer, 16:675-702, 2009.
18. Arteaga CL, O'Neill A, Moulder SL, et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res, 14:6277-6283, 2008.
19. Narayan M, Wilken JA, Harris LN, et al. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res, 69:2191-2194, 2009.
20. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol, 28:1138-1144, 2010.
21. Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res, 15:2552-2558, 2009.
22. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol, 28:1301-1307, 2010.
23. Chandarlapaty S, King T, Sakr R, et al. Hyperactivation of the PI3K-AKT pathway commonly underlies resistance to trastuzumab in HER2 amplified breast cancer. Cancer Res, 69 (24 Suppl.): Abstract 709, 2009.
24. Vogel CL, Burris HA, Limentani S, et al. A phase II study of trastuzumab-DM1 (TDM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. J Clin Oncol, 27 (15 S): 45s (Abstract 1017), 2009.